- Home
- BKE vs KNSA Comparison
BKE vs KNSA Comparison
Compare BKE & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BKE | KNSA |
|---|---|---|
| Founded | 1948 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.6B |
| IPO Year | 1992 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BKE | KNSA |
|---|---|---|
| Price | $50.60 | $42.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $55.00 | $52.33 |
| AVG Volume (30 Days) | 589.9K | ★ 640.8K |
| Earning Date | 03-13-2026 | 02-24-2026 |
| Dividend Yield | ★ 8.72% | N/A |
| EPS Growth | ★ 3.79 | N/A |
| EPS | ★ 4.09 | 0.47 |
| Revenue | ★ $1,277,894,000.00 | $597,973,000.00 |
| Revenue This Year | $7.42 | $62.70 |
| Revenue Next Year | $2.75 | $31.18 |
| P/E Ratio | ★ $12.35 | $93.22 |
| Revenue Growth | 4.67 | ★ 55.68 |
| 52 Week Low | $33.12 | $18.12 |
| 52 Week High | $61.69 | $45.50 |
Technical Indicators
Market Signals| Indicator | BKE | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 45.06 | 49.31 |
| Support Level | $46.59 | $42.99 |
| Resistance Level | $49.49 | $45.50 |
| Average True Range (ATR) | 1.76 | 1.66 |
| MACD | -0.02 | 0.10 |
| Stochastic Oscillator | 43.66 | 56.70 |
Price Performance
Historical ComparisonAbout BKE Buckle Inc. (The)
Buckle Inc is a retailer of casual apparel, footwear, and accessories. The company retails medium to affordable priced casual apparel, footwear, and accessories for fashion-conscious young men and women. It retails under the brand names 'Buckle' and 'The Buckle'. Buckle markets a wide selection of mostly brand-name casual apparel including denim, other casual bottoms, tops, sportswear, outerwear, accessories, and footwear.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.